Advertisement

Investigational New Drugs

, Volume 37, Issue 4, pp 797–797 | Cite as

Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

  • Glen J. WeissEmail author
  • Lisa Blaydorn
  • Julia Beck
  • Kirsten Bornemann-Kolatzki
  • Howard Urnovitz
  • Ekkhard Schütz
  • Vivek Khemka
Correction
  • 264 Downloads
Correction to: Invest New Drugs (2018) 36:96–102
Fig. 1

PFS for chemotherapy treatment naïve PDAC (n = 12). The solid line shows PFS. The hashed line shows the 95% CI (confidence interval) for the curve

Fig. 2

OS for chemotherapy treatment naïve PDAC (n = 12). The solid line shows OS. The hashed line shows the 95% CI for the curve

  https://doi.org/10.1007/s10637-017-0525-1

The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct. It was also noted that the upper value for the 95% CI had an error in both figures. Both graphs have been regenerated using the published PFS and OS data presented in Table 2 and the corrected 95% CIs are included. These changes do not impact the overall results of the data or the conclusions presented in the publication. We sincerely apologize for this oversight.

Notes

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Glen J. Weiss
    • 1
    • 2
    Email author
  • Lisa Blaydorn
    • 1
  • Julia Beck
    • 3
  • Kirsten Bornemann-Kolatzki
    • 3
  • Howard Urnovitz
    • 3
  • Ekkhard Schütz
    • 3
  • Vivek Khemka
    • 1
    • 4
  1. 1.Western Regional Medical CenterCancer Treatment Centers of AmericaGoodyearUSA
  2. 2.University of Arizona College of Medicine-PhoenixPhoenixUSA
  3. 3.Chronix BiomedicalGöttingenGermany
  4. 4.Virginia G. Piper Cancer CenterScottsdaleUSA

Personalised recommendations